Rigel Pharmaceuticals, Inc. beat EPS estimates 0% of the time across 1 reported quarters (0 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $0.91 | — | — | Miss |
| Q12026 FY2026 | $0.74 | $0.44 | -40.5% | Miss |
| 2026-03-03 | $1.33 | — | — | Miss |
Back to RIGL overview · RIGL holders · RIGL KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.